Chronic Psychiatric Disease Management - USMLE Step 3

1. Which of the following is the most appropriate next step in managing this patient's depression?
   Answer: Augment the current sertraline regimen with aripiprazole. The correct answer is B. This patient has had a partial response to an adequate trial (sufficient dose and duration) of an SSRI. In cases of partial response, augmentation is often more effective than switching to another agent within the same class. Atypical antipsychotics like aripiprazole, quetiapine, and brexpiprazole are FDA-approved and evidence-based augmentation agents for major depressive disorder. Switching to another SSRI (A) is a reasonable strategy but generally reserved for non-response or intolerance. Increasing sertraline beyond its maximum recommended dose of 200 mg (C) is not evidence-based and increases the risk of side effects. Adding a benzodiazepine (D) does not target core depressive symptoms and is inappropriate for long-term management.
2. Which of the following is the most appropriate addition to his lithium regimen?
   Answer: Lurasidone The correct answer is B. The patient is experiencing a breakthrough depressive episode despite being on maintenance lithium. The primary concern in treating bipolar depression is to avoid inducing mania or rapid cycling. Antidepressant monotherapy (A, C) carries a significant risk of this switch and is generally avoided. The evidence-based approach is to add a medication with proven efficacy for bipolar depression. Lurasidone is an atypical antipsychotic that is FDA-approved for this indication. Other options include quetiapine, olanzapine-fluoxetine combination, or cariprazine. Adding another mood stabilizer like valproic acid (D) is an option for prophylaxis but is not a first-line acute treatment for bipolar depression.
3. Which of the following is the most appropriate recommendation for this patient's perioperative management?
   Answer: Coordinate with anesthesia to hold buprenorphine for 24-72 hours preoperatively and use a multimodal non-opioid pain regimen. The correct answer is C. Management of buprenorphine in the perioperative period requires careful coordination. Buprenorphine is a partial mu-opioid agonist with high receptor affinity, which can interfere with the efficacy of full agonist opioids used for analgesia. While continuing it (A) is one strategy ('continue and override'), a common and effective approach involves holding the buprenorphine for a short period (24-72 hours) before surgery to allow full agonists to work. This must be paired with a robust multimodal pain plan (e.g., regional anesthesia, NSAIDs, acetaminophen) and close monitoring. Stopping it for a prolonged period (B) dramatically increases the risk of withdrawal and relapse. Transitioning to methadone (D) is a complex process not indicated for routine elective surgery.
4. Which of the following is the most appropriate next step in managing his ADHD and new-onset symptoms?
   Answer: Cross-taper from mixed amphetamine salts to atomoxetine. The correct answer is D. Stimulant medications are known to increase blood pressure, heart rate, anxiety, and insomnia. This patient's new-onset hypertension and anxiety are likely side effects of his long-term stimulant use. The most appropriate step is to address the root cause by switching to a non-stimulant medication for ADHD, such as atomoxetine, viloxazine, or guanfacine/clonidine ER. Simply treating the side effects with other medications (A, B) leads to polypharmacy and does not address the underlying iatrogenic issue. While lifestyle changes (C) are important, the degree of hypertension requires a medication adjustment.
5. What is the most appropriate strategy for discontinuing lorazepam in this patient?
   Answer: Switch to an equivalent dose of diazepam and then slowly taper. The correct answer is B. Long-term, high-dose benzodiazepine use requires a very slow taper to minimize withdrawal symptoms. A direct taper of a short-acting agent like lorazepam can be difficult due to significant inter-dose rebound anxiety. The preferred method is to switch the patient to an equivalent dose of a long-acting benzodiazepine, such as diazepam or clonazepam. The long half-life of these agents provides a smoother, more gradual decline in blood levels, making the taper more tolerable. A 25% per week taper (A) is too rapid for long-term use. Abrupt cessation (C) can cause severe, life-threatening withdrawal. Switching to another short-acting agent like alprazolam (D) would not facilitate the taper.
6. Which of the following is the most appropriate pharmacologic agent to initiate in this patient?
   Answer: Sertraline When treating depression in elderly patients, you need to consider both efficacy and safety, particularly focusing on side effects that could worsen existing comorbidities like falls risk, cardiovascular disease, and diabetes. Sertraline (A) is the best choice here because it's a selective serotonin reuptake inhibitor (SSRI) with minimal drug interactions, low anticholinergic effects, and minimal impact on cardiac conduction. It has a favorable side effect profile in the elderly and doesn't significantly affect blood glucose or increase fall risk through sedation or orthostatic hypotension. Paroxetine (B) is problematic because it has the highest anticholinergic activity among SSRIs, which can cause confusion, constipation, urinary retention, and dry mouth in elderly patients. It also has significant drug interactions and can worsen cognitive function. Amitriptyline (C) is a tricyclic antidepressant that's particularly dangerous in the elderly due to strong anticholinergic effects, sedation, orthostatic hypotension, and cardiac conduction abnormalities. Given this patient's fall history and multiple comorbidities, amitriptyline could significantly increase her fall risk and worsen her diabetes management. Mirtazapine (D) causes significant sedation and weight gain, both problematic for this patient. The sedation increases fall risk, while weight gain can worsen diabetes control and mobility issues. Study tip: For elderly depression questions on USMLE Step 3, remember "start low, go slow" with medications that have minimal anticholinergic effects, low fall risk, and few drug interactions. Sertraline and citalopram are typically the safest SSRI choices in geriatric patients.
7. Which of the following is the most appropriate next pharmacologic step?
   Answer: Augment fluoxetine with a low dose of risperidone. The correct answer is B. This patient has treatment-resistant OCD, defined as a failure to respond to an adequate trial of a first-line agent (an SSRI at maximum tolerated dose for at least 8-12 weeks) plus ERP. The most evidence-based next step is to augment the SSRI with an atypical antipsychotic, such as risperidone or aripiprazole. Switching to clomipramine (A), a tricyclic antidepressant, is another option, but augmentation is often preferred to preserve the partial response from the SSRI. Increasing the fluoxetine dose beyond the typical maximum (C) is not evidence-based. Augmentation with buspirone (D) has limited evidence for OCD.
8. Which of the following is the most appropriate management plan regarding his antipsychotic medication during the transition period?
   Answer: Continue the current dose of oral risperidone for 3 weeks after the first injection. The correct answer is C. Risperidone long-acting injectable microspheres (Risperdal Consta) has a delayed onset of action, as the medication is slowly released from the microspheres. Therapeutic plasma concentrations are not reached for approximately 3 weeks after the initial injection. Therefore, oral antipsychotic supplementation (in this case, the patient's current oral risperidone) must be continued for the first 3 weeks to ensure continuous therapeutic coverage and prevent relapse.
9. A 32-year-old man with bipolar I disorder is stable for 2 years on lithium ER 600 mg twice daily. He starts ibuprofen frequently for a new running injury. At follow-up he reports mild tremor and increased thirst but mood remains stable. Vitals normal. Labs: lithium trough 1.3 mEq/L (previously 0.9), creatinine 1.1 mg/dL (baseline 0.9), sodium 139 mEq/L, TSH 4.8 mIU/L. He denies suicidal ideation and wants to keep running. What is the most appropriate next step in managing this patient's condition?
   Answer: Review NSAID interaction, reduce lithium dose, and repeat level and renal tests This question tests chronic psychiatric disease management skills at the level expected for USMLE Step 3, focusing on long-term care strategies. Chronic psychiatric management involves a comprehensive approach including medication management, psychosocial interventions, and regular monitoring. In this scenario, the patient's history and current presentation suggest lithium toxicity from NSAID interaction, necessitating dose reduction and monitoring. Choice B is correct because it aligns with the latest clinical guidelines for managing bipolar disorder, addressing both symptoms and side effects effectively. Choice A is incorrect because it reflects an outdated practice not supported by current evidence, often leading to worsened toxicity. To assist learning, emphasize the importance of integrating psychosocial factors into management plans and staying updated on guideline changes. Encourage practice in identifying cultural and individual patient factors that influence treatment choices.
10. What is the most appropriate recommendation regarding her mood stabilizer?
    Answer: Plan for a gradual cross-taper from valproic acid to lamotrigine. When you encounter preconception counseling questions involving psychiatric medications, you need to balance maternal mental health stability against teratogenic risks while considering safer alternatives. Valproic acid poses significant teratogenic risks, including neural tube defects (1-2% risk), facial dysmorphism, and cognitive impairment in exposed children. For a woman planning pregnancy, continuing valproic acid is inappropriate despite her current stability. The goal is transitioning to a safer mood stabilizer before conception while maintaining psychiatric stability. Lamotrigine represents the safest mood stabilizer option during pregnancy, with minimal teratogenic risk and effectiveness for bipolar disorder maintenance. A gradual cross-taper allows for smooth transition while monitoring for mood destabilization, making option D correct. Option A is dangerous because while folic acid reduces neural tube defect risk, it doesn't eliminate valproic acid's other teratogenic effects, and continuing this high-risk medication is unjustifiable when safer alternatives exist. Option B fails to recognize that untreated bipolar disorder during pregnancy carries substantial risks including poor prenatal care, substance abuse, and postpartum psychosis. Abrupt discontinuation also risks severe mood episodes. Option C contains a critical misconception - lithium does carry fetal risks, particularly Ebstein's anomaly (though the risk is lower than previously thought, around 0.05-0.1%). While lithium might be considered, lamotrigine remains the preferred first-line option. Remember: In psychiatric preconception counseling, never choose "stop everything" or continue high-risk medications. Look for the safest effective alternative with proper transition planning.
11. Which of the following is the most appropriate immediate response by the physician?
    Answer: Validate her distress and remind her to use the skills outlined in her crisis plan. The correct answer is C. The cornerstone of managing borderline personality disorder (BPD) is skills-based psychotherapy (like DBT). A key principle is to avoid reinforcing maladaptive behaviors (e.g., threats of self-harm to obtain medication). The most appropriate response is to validate the patient's emotional pain while simultaneously empowering her to use her previously learned coping skills and crisis plan. Prescribing a benzodiazepine (A) can be dangerous, reinforce dysfunctional behavior, and increase disinhibition. While an ED visit (B) may become necessary if she cannot ensure her safety, the first step is to encourage the use of her established plan. Reactive medication changes (D) are generally ineffective for BPD traits and can destabilize the treatment frame.
12. Which of the following would be the most appropriate long-term maintenance monotherapy for this patient?
    Answer: Paliperidone When you encounter schizoaffective disorder questions, remember this condition requires treatment for both psychotic symptoms (hallucinations/delusions) and mood episodes. The key is that psychotic symptoms persist even when mood is stable, distinguishing it from mood disorders with psychotic features. For schizoaffective disorder, bipolar type, you need a medication that addresses three components: acute mood stabilization, mood episode prevention, and ongoing psychotic symptoms. Paliperidone (A) is an atypical antipsychotic with demonstrated efficacy for all three aspects. It effectively treats psychotic symptoms while also providing mood stabilization, making it an excellent monotherapy choice for long-term maintenance. Sertraline (B) is an SSRI antidepressant that would address depressive episodes but provides no antipsychotic effect for her persistent hallucinations. Additionally, using an antidepressant alone in bipolar disorder risks triggering manic episodes. Lithium (C) is a classic mood stabilizer excellent for bipolar disorder, particularly manic episode prevention, but it lacks antipsychotic properties. Her persistent auditory hallucinations would remain untreated. Lamotrigine (D) is primarily effective for bipolar depression prevention and offers minimal benefit for manic episodes or psychotic symptoms. It wouldn't address her euphoric episodes or hallucinations adequately. Study tip: For schizoaffective disorder questions, always look for treatments that address both psychotic and mood symptoms simultaneously. Atypical antipsychotics are often the best monotherapy choice because they provide broader symptom coverage than mood stabilizers or antidepressants alone.
13. Which of the following is the most appropriate next step in management?
    Answer: Initiate treatment with valbenazine and consider switching antipsychotics. The correct answer is C. The patient is exhibiting classic signs of tardive dyskinesia (TD), a potentially irreversible hyperkinetic movement disorder caused by long-term exposure to dopamine receptor antagonists. The first steps in management are to reduce the dose of the offending agent or switch to a lower-risk antipsychotic (e.g., a second-generation agent like clozapine or quetiapine) if possible. Additionally, VMAT2 inhibitors like valbenazine or deutetrabenazine are approved for the treatment of TD. Administering an anticholinergic agent like benztropine (A, B) is the treatment for acute dystonia or parkinsonism, but it can worsen TD. The movements are not benign (D) and can be socially stigmatizing and physically uncomfortable.
14. What is the most appropriate recommendation regarding the duration of his pharmacotherapy?
    Answer: He should continue sertraline for at least another 12 months while stable before considering a taper. When you encounter PTSD medication management questions, focus on the evidence-based guidelines for maintenance therapy duration, especially in patients who've achieved stability through combined treatment approaches. This veteran represents an ideal treatment response - he's completed evidence-based psychotherapy (CPT), achieved symptom remission on sertraline, and maintained functional recovery for a full year. Current PTSD treatment guidelines recommend continuing effective pharmacotherapy for at least 12 months after achieving symptom stability before considering discontinuation. This approach minimizes relapse risk while the patient consolidates therapeutic gains. Option D is correct because it follows established guidelines: maintain stable patients on effective medication for at least 12 months post-stabilization before attempting a gradual taper. This patient has been stable for one year, so continuing for "at least another 12 months" ensures adequate consolidation time. Option A is overly conservative - indefinite treatment isn't necessary for all PTSD patients, especially those with good psychotherapy response and stable remission. Option B ignores the synergistic relationship between psychotherapy and pharmacotherapy; completing CPT doesn't eliminate the need for continued medication stabilization. Option C proposes premature discontinuation with inadequate tapering time - stopping effective PTSD medication after only one year of stability significantly increases relapse risk, and 2-4 weeks is too rapid for safe sertraline discontinuation. Remember: PTSD medication decisions should balance relapse prevention with treatment burden. Stable patients need at least 12 months of continued pharmacotherapy before considering discontinuation, regardless of psychotherapy completion.
15. In addition to a basic metabolic panel and lithium level, which of the following tests is most important to obtain as part of her routine annual monitoring?
    Answer: Thyroid-stimulating hormone level The correct answer is C. Long-term lithium therapy can cause hypothyroidism in up to one-third of patients, and it can also affect parathyroid function (hyperparathyroidism and hypercalcemia) and renal function (nephrogenic diabetes insipidus, chronic kidney disease). Therefore, routine annual monitoring for a stable patient on chronic lithium therapy should include a TSH level, as well as a basic metabolic panel (to assess renal function and electrolytes) and a lithium level. Liver function tests are necessary for valproate, an ECG may be needed at baseline or with signs of toxicity but not typically annually unless indicated, and a CBC is for carbamazepine.
16. Which of the following is the most appropriate next step in management?
    Answer: Add a low dose of bupropion to her current regimen. The correct answer is C. SSRI-induced sexual dysfunction is a common and distressing side effect. For a patient who has responded well to the SSRI and wishes to continue it, augmentation with bupropion is a first-line strategy. Bupropion is a norepinephrine-dopamine reuptake inhibitor that often improves sexual function and can also augment the antidepressant effect. Reassurance (A) is inappropriate as the side effect has persisted for 9 months. Switching to venlafaxine (an SNRI) (B) is unlikely to help, as SNRIs also have high rates of sexual dysfunction. Drug holidays (D) are not recommended for antidepressants with intermediate half-lives like escitalopram and can lead to withdrawal symptoms or breakthrough depression.
17. Which of the following is the most appropriate counseling to provide this patient?
    Answer: Recommend a very gradual taper of the paroxetine dose over a period of 2 to 4 months. When managing panic disorder treatment discontinuation, you must balance the patient's desire for independence with evidence-based tapering practices to prevent relapse and withdrawal symptoms. The correct approach is option A - recommending a very gradual taper over 2-4 months. SSRIs like paroxetine have short half-lives and are particularly associated with discontinuation syndrome, which can include dizziness, flu-like symptoms, and "brain zaps." More importantly, panic disorder has high relapse rates with abrupt medication cessation, even in patients who've been stable. A slow taper allows monitoring for symptom recurrence while minimizing withdrawal effects. Since this patient has strong CBT skills, gradual discontinuation is reasonable to attempt. Option B is too rigid - while panic disorder often requires long-term treatment, indefinite therapy isn't automatically necessary for every patient, especially those with good CBT response and prolonged stability. Option C represents dangerous advice, as immediate cessation risks both withdrawal syndrome and panic symptom recurrence without warning. The one-year stability period, while encouraging, doesn't guarantee sustained remission off medication. Option D suggests replacing a proven treatment with PRN benzodiazepines, which is inappropriate for panic disorder maintenance and risks creating dependence while providing inadequate prophylaxis. Remember for Step 3: Medication discontinuation questions often test your knowledge of tapering schedules and relapse prevention. Always favor gradual approaches for psychiatric medications, especially SSRIs and particularly paroxetine, which has the highest discontinuation syndrome risk among this drug class.
18. Which of the following is the most appropriate change to his medication regimen?
    Answer: Initiate a gradual cross-taper from olanzapine to ziprasidone. The correct answer is C. Olanzapine is associated with a high risk of metabolic side effects, including significant weight gain, hyperglycemia, and dyslipidemia. This patient has developed iatrogenic metabolic syndrome. While metformin (A) can be a helpful adjunct, the primary intervention should be to address the offending agent. The most appropriate step is to switch the patient to an antipsychotic with a lower metabolic risk profile, such as ziprasidone, aripiprazole, or lurasidone. Increasing the olanzapine dose (B) would likely worsen the metabolic issues. Bariatric surgery (D) is a significant intervention that may be considered later, but a medication change should be attempted first.
19. Which of the following is the most appropriate initial dosing and titration schedule for lamotrigine in this patient?
    Answer: Start at 25 mg every other day for 2 weeks, then increase to 25 mg daily. The correct answer is B. Valproic acid significantly inhibits the metabolism of lamotrigine, more than doubling its serum concentration. To reduce the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), a much slower titration schedule is required when lamotrigine is co-administered with valproate. The recommended starting dose is 25 mg every other day for two weeks. The standard titration (A) is for lamotrigine monotherapy. A faster titration (C, D) would be used with an enzyme-inducing medication (like carbamazepine) but would be extremely dangerous in this patient taking valproate, markedly increasing the risk of a life-threatening rash.
20. Which of the following is the most appropriate medication to initiate during this hospitalization?
    Answer: Clozapine When you encounter a schizophrenia case describing failed trials with multiple antipsychotics, you're likely dealing with treatment-resistant schizophrenia (TRS). The key diagnostic criteria for TRS are: failure to respond to at least two adequate trials of different antipsychotics, each lasting 4-6 weeks at therapeutic doses, with continued psychotic symptoms. This patient clearly meets TRS criteria with failed 12-week risperidone and 16-week aripiprazole trials at appropriate doses, demonstrating persistent auditory hallucinations and paranoid delusions. Clozapine (D) is the gold standard for TRS and the only FDA-approved medication specifically for this indication. It's uniquely effective because it blocks multiple neurotransmitter receptors beyond just dopamine, including serotonin and norepinephrine pathways. Olanzapine (A) is another second-generation antipsychotic, but switching to yet another conventional antipsychotic after two failures rarely provides benefit. Haloperidol (B) is a first-generation antipsychotic that's actually less likely to work than the second-generation agents already tried, plus carries higher risk of extrapyramidal side effects. Ziprasidone (C) is another second-generation antipsychotic with no special indication for treatment-resistant cases. While clozapine requires careful monitoring for potentially serious side effects like agranulocytosis (weekly blood draws initially), neutropenia, and myocarditis, its superior efficacy in TRS makes it the clear choice when other antipsychotics have failed. Study tip: Remember the "rule of twos" for TRS—two failed trials of different antipsychotics automatically points to clozapine as the next step.

Start this quiz